financetom
Business
financetom
/
Business
/
ServisFirst Bancshares' Q3 EPS up 18.2% driven by loan growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ServisFirst Bancshares' Q3 EPS up 18.2% driven by loan growth
Oct 20, 2025 1:34 PM

Overview

* ServisFirst Q3 adjusted EPS grows 18.2% yr/yr, reflecting strong earnings growth

* Company net interest margin rises 25 bps yr/yr despite impact from non-accrual relationship

* ServisFirst sells $83.4 mln of low-yielding bonds, reinvests in higher-yield securities

Outlook

* Company did not provide specific guidance for future quarters or full year in press release.

Result Drivers

* LOAN AND DEPOSIT GROWTH - Co reports loans grew by $973.7 mln, or 7.9%, and deposits grew by $960.4 mln, or 7.3%, yr/yr

* NET INTEREST MARGIN EXPANSION - CFO David Sparacio highlights expansion of net interest margin and pricing discipline on loans and deposits

* PORTFOLIO RESTRUCTURING - Co sold $83.4 mln of low-yielding bonds at a loss, reinvested in higher-yield securities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $1.20

Q3 Net $65.57

Income mln

Q3 Net $133.44

Interest mln

Income

Q3 $9.46

Credit mln

Loss

Provisio

n

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy."

* Wall Street's median 12-month price target for ServisFirst Bancshares Inc ( SFBS ) is $91.00, about 17.4% above its October 17 closing price of $75.21

* The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Hyatt Strikes Licensing Deal With The Venetian Resort Las Vegas
Hyatt Strikes Licensing Deal With The Venetian Resort Las Vegas
Dec 18, 2024
12:25 PM EST, 12/18/2024 (MT Newswires) -- Hyatt Hotels ( H ) and The Venetian Resort Las Vegas said Wednesday that they agreed to a long-term licensing deal to make the property on the Las Vegas Strip bookable through Hyatt channels. The channels include Hyatt.com and the World of Hyatt mobile app, according to the statement. Financial terms were not...
HPQ Silicon Updates Battery Milestones Achieved by Novacium
HPQ Silicon Updates Battery Milestones Achieved by Novacium
Dec 18, 2024
12:29 PM EST, 12/18/2024 (MT Newswires) -- HPQ Silicon ( HPQFF ) on Wednesday updated shareholders on the latest battery milestones achieved by its France-based affiliate, Novacium SAS. Latest results confirmed that, over 650 cycles, 18,650 batteries made with Novacium's GEN3 silicon-based anode material delivered a cumulative energy return of 2,296 Ampere-Hours (Ah), while graphite benchmark batteries, made with high-grade...
Update: Market Chatter: DLocal Weighing Potential Sale, Other Options
Update: Market Chatter: DLocal Weighing Potential Sale, Other Options
Dec 18, 2024
12:24 PM EST, 12/18/2024 (MT Newswires) -- (Updates to add DLocal's ( DLO ) response in the fourth paragraph and recent stock price movement in the fifth paragraph.) DLocal ( DLO ) is exploring a potential sale, among other options, Reuters reported Wednesday, citing unnamed people familiar with the matter. The Latin American payments provider is working with Morgan Stanley...
MetaVia Reports Positive Phase 2a Results for DA-1241 in Presumed MASH Patients
MetaVia Reports Positive Phase 2a Results for DA-1241 in Presumed MASH Patients
Dec 18, 2024
12:25 PM EST, 12/18/2024 (MT Newswires) -- MetaVia ( MTVA ) shares were down 26% in recent Wednesday trading after the company reported positive results from its two-part phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH. Part 1 of the trial is evaluating DA-1241, which is a novel g-protein-coupled receptor 119 agonist, against...
Copyright 2023-2026 - www.financetom.com All Rights Reserved